NON-ALCOHOLIC FATTY LIVER DISEASE

This study aims to understand how weight-loss surgery helps control health problems linked to severe obesity, such as type 2 diabetes and sleep apnea. Researchers will follow 35 patients who are already scheduled for a specific type of weight-loss surgery (mini-gastric bypass) as…

This study is testing if a medication called empagliflozin, currently used for diabetes, can safely reduce fat in the liver of obese teenagers with non-alcoholic fatty liver disease (NAFLD). Forty adolescents will take the drug or a placebo for 26 weeks while also receiving lifes…

This large, late-stage study is testing whether a new drug called efimosfermin alfa is safe and can help control a type of fatty liver disease called MASH. It will involve about 1,250 adults with moderate liver scarring to see if the drug can reduce fat and stiffness in the liver…

This study is testing if a medication called semaglutide, currently used for diabetes, can help people with non-alcoholic fatty liver disease (NAFLD). Researchers want to see if the drug can reduce liver fat and inflammation. They are also studying how the liver reacts to sugar t…

This study is testing if time-restricted eating (a form of intermittent fasting) can reduce fat in the liver for adults who have non-alcoholic fatty liver disease (NAFLD) but are not obese. Researchers want to see if this lifestyle change, independent of major weight loss, can be…

This study is testing whether a minimally invasive endoscopic procedure to reduce stomach size, combined with lifestyle changes, is better than lifestyle changes alone for treating a serious fatty liver disease called MASH in people with obesity. Researchers will compare the two …

This study is testing whether a 6-month lifestyle program can help improve memory, reasoning, and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD). Researchers are enrolling 45 participants aged 18-42 who will be randomly assigned to receive general health ad…

This large, late-stage study is testing whether a new drug called efimosfermin alfa can help people with a serious form of fatty liver disease called MASH. The main goal is to see if the drug can reduce liver scarring and fat buildup over one year, compared to a placebo. The stud…

This study is testing if time-restricted eating (eating all meals within an 8-hour window each day) can help reduce fat in the liver for people with fatty liver disease. It will compare this approach to standard lifestyle advice, which includes a healthy diet and regular exercise…

This study aims to find better, non-invasive ways to diagnose liver scarring (fibrosis) in people with fatty liver disease. Researchers will collect blood samples from 575 participants and compare new blood tests and AI-powered ultrasound to the current gold standard, a liver bio…

This study aims to find liver scarring earlier by combining multiple tests into one smarter system. Researchers will analyze blood, genetics, and gut bacteria from 1,200 people at risk for liver disease. The goal is to create a better tool that catches problems sooner, so fewer p…

This study is testing a new, quick ultrasound method to check for liver scarring (fibrosis) in overweight patients with fatty liver disease (NAFLD/NASH). Researchers want to see if this method, done during a routine stomach scope, is more accurate than other non-invasive tests fo…

This early-stage study aims to understand how a single dose of an experimental drug called efimosfermin alfa is processed by the body and how safe it is for adults with varying degrees of liver damage caused by fatty liver disease. It will enroll 32 participants with moderate to …

This study aims to understand a puzzle in early diabetes: why the liver might stop responding to insulin's signal to lower blood sugar but keep making fat. Researchers will give a single dose of a drug called alpelisib or a placebo to healthy adults and adults at risk for type 2 …

This early-stage study aims to check the safety and how the body processes a single dose of efimosfermin alfa, a potential future treatment for non-alcoholic fatty liver disease. Researchers will enroll 30 healthy participants of Chinese, Japanese, and White/European ancestry to …

This study aims to understand how the diabetes drug pioglitazone affects energy production inside liver cells in people with Type 2 diabetes and fatty liver disease (NAFLD or NASH). Researchers will measure chemical processes in the liver before and after 16 weeks of treatment. T…

This study aims to collect blood and tissue samples from 800 patients with various chronic liver diseases and liver cancer. Researchers will use these samples to create better laboratory models, like mini-tumors in dishes and mice, to study how these diseases progress and to test…

This study aims to understand the connection between gut bacteria and several chronic liver diseases. Researchers will compare blood and stool samples from 3,000 adult patients with conditions like autoimmune hepatitis and fatty liver disease to samples from their healthy househo…

This study aims to find out how many adults in Olmsted County, Minnesota, have a common liver condition called NAFLD (fatty liver disease) and its more serious form, NASH. Researchers will enroll 800 local residents to gather detailed health information and track their long-term …